Effects of stopping parenteral nutrition and IGF-1 on very low birth weight infants
The Effects of Time Points to Cease Parenteral Nutrition and IGF-1 on Very Low Birth Weight Infants--A Multicenter Prospective Cohort Study
This study is trying to see how stopping special nutrition and the hormone IGF-1 affects the growth of very low birth weight babies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 416 (estimated) |
| Sex | All |
| Sponsor | Peking University Academic / other |
| Locations | 1 site (Xingtai, Hebei) |
| Trial ID | NCT06071403 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the short-term and long-term effects of the timing of ceasing parenteral nutrition on the growth of very preterm infants. It will also investigate the role of insulin-like growth factor 1 (IGF-1) in mediating the relationship between nutrient volume and growth in these infants. The study will involve a prospective cohort design, focusing on infants with a birth weight of less than 1500 grams admitted shortly after birth. Researchers will analyze how different cessation times and nutrient volumes impact growth outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are infants with a birth weight less than 1500 grams who are admitted within 72 hours after birth.
Not a fit: Patients with congenital abnormalities or those who survive less than 7 days after birth may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into optimal nutrition management for very low birth weight infants, potentially improving their growth outcomes.
How similar studies have performed: While the specific approach of this study may be novel, previous research has indicated the importance of nutrition timing and IGF-1 in growth outcomes for preterm infants.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Infants with a birth weight less than 1500 grams 2. Infants admitted within 72 hours after birth 3. Infants born from July 1, 2023, to June 30, 2024 4. Written informed consent from parents or guardians Exclusion Criteria: 1. Infants with congenital abnormality 2. Infants surviving \<7 days after birth
Where this trial is running
Xingtai, Hebei
- Wei Guo — Xingtai, Hebei, China (Recruiting)
Study contacts
- Study coordinator: Shuaijun Li, doctor
- Email: 18811331226@163.com
- Phone: 18811331226
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.